Anogen-Yes Biotech

02/18/2026

A study published in Biology Direct reveals how hypoxia influences microglia and promotes glioma growth through inflammatory cytokine secretion.
Researchers used Anogen’s Multiplex Human Cytokine ELISA Kit (EM10001) to measure cytokines like IL-1β, IL-6, TNF-α, and more, uncovering how IL-1β–NF-κB–heparanase signaling drives tumor progression in glioma.

Anogen is proud to support cancer research with trusted ELISA kits and antibodies.
Learn more: www.anogen.ca

https://www.youtube.com/watch?v=9tCdiFlMWmc

🧠 TREM2 & Inflammation: New Insights into Alzheimer’s DiseaseA recent study highlights the key role of TREM2 in regulating inflammatory responses in macroph...

02/11/2026

A small open-label clinical trial in individuals with dominantly inherited Alzheimer’s disease (DIAD) suggests that tau immunotherapy may significantly reduce tau-related biomarkers in both cerebrospinal fluid (CSF) and plasma.

After treatment, levels of phosphorylated tau and other tangle-associated markers declined noticeably, indicating that the antibody therapy may be engaging its intended target and affecting tau pathology biology. While the study was small and not placebo-controlled, the biomarker reductions provide encouraging biological evidence that anti-tau immunotherapy can alter disease-related processes.

Researchers emphasized that larger, controlled trials are still needed to determine whether these biomarker changes translate into meaningful clinical benefit.

Read the full article: https://www.alzforum.org/news/conference-coverage/after-tau-immunotherapy-tangle-markers-tank-csf-plasma #:~:text=In%20a%20small%2C%20open%2Dlabel%20trial%20in%20people,inherited%20Alzheimer's%20disease%20(DIAD)%2C%20the%20tau%20immunotherapy

After Tau Immunotherapy, Tangle Markers Tank in CSF, Plasma Go to another part Series - Clinical Trials on Alzheimer's Disease (CTAD) 2025: Quick Links Article Comments References Further Reading Tools Add to my Library Follow News Comments Share How would you like to share? Facebook X LinkedIn Back...

02/05/2026

A major new study has mapped the detailed chemical landscape of the tau protein — a hallmark of over 20 neurodegenerative diseases including Alzheimer’s and CTE — with unprecedented precision. Researchers analyzed brain tissue from 203 patients across multiple tauopathies using a cutting-edge mass spectrometry tool (FLEXITau) that quantifies specific pathological forms of tau.

Instead of broad, “one-size-fits-all” approaches, this tau atlas identifies 145 post-translational modifications and 195 cleavage sites, ranked by disease relevance through machine learning. That gives scientists and drug developers a detailed roadmap of which tau forms to target for diagnostics, imaging, and therapies.

This resource not only informs better precision diagnostics but could also accelerate targeted therapeutic development — and the methodology may be adaptable to other disease-related proteins beyond tau.

Read the full article: https://medicalxpress.com/news/2026-01-molecular-atlas-tau-enables-precision.html

Tau protein aggregation is a shared feature in over 20 neurodegenerative diseases (collectively referred to as "tauopathies"). New research led by Boston Children's Hospital challenges the current "one-size-fits-all" approach to diagnosing and treating these tauopathies. The study is published in th...

01/28/2026

A Cell Perspective outlines how the field is evolving beyond traditional amyloid-focused treatments to include tau-targeted approaches, neuroinflammation modulation, and multi-modal strategies that better address the complexity of Alzheimer’s disease. These insights highlight a broader therapeutic landscape with potential for future breakthroughs.

Read the full article: https://www.cell.com/cell/fulltext/S0092-8674(25)01368-6

Emerging tau-targeting approaches show promise in slowing Alzheimer’s disease progression, complementing recent advances in FDA-approved anti-Aβ therapies. This perspective outlines the progress in Alzheimer’s disease therapeutic development, highlighting how tau trial outcomes are providing in...

01/22/2026

An early-stage clinical trial has shown that VY7523, an investigational anti-tau agent, demonstrated a positive safety and tolerability profile in patients with early Alzheimer’s disease. As tau pathology is strongly linked to neurodegeneration and cognitive decline, these findings support continued exploration of tau-targeted therapies as a promising avenue beyond amyloid-focused approaches.

🔬 Early safety success is a critical step toward developing disease-modifying treatments for Alzheimer’s.

Read the full article here: https://www.neurologylive.com/view/anti-tau-agent-vy7523-demonstrates-positive-safety-early-alzheimer-trial

Overall, treatment with the anti-tau monoclonal antibody resulted in no serious or severe adverse events, with additional results expected to be presented at an upcoming scientific conference.

01/14/2026

Anti-amyloid monoclonal antibodies—like lecanemab and donanemab—are changing the landscape of Alzheimer’s disease care by targeting amyloid-β plaques, a core driver of disease. These therapies have shown robust plaque removal and modest slowing of cognitive decline in early AD patients with confirmed amyloid pathology. While challenges remain, this progress marks a pivotal step toward precision neurology and more effective, tailored interventions for Alzheimer’s.

Read the full article here: https://pmc.ncbi.nlm.nih.gov/articles/PMC12470750/

Alzheimer’s disease (AD) is the most common cause of dementia, pathologically defined by extracellular amyloid-β (Aβ) plaques and intracellular tau neurofibrillary tangles. Recent U.S. Food and Drug Administration (FDA) approvals of anti-amyloid ...

01/07/2026

In 2018 alone, 9.6 million lives were lost to cancer, making it the second leading cause of death globally.

At Anogen, we believe the future of cancer therapy lies in personalization. Immune checkpoint inhibitors—such as PD-1 and PD-L1–targeted therapies, hold tremendous promise, especially when tailored to the unique immune profile of each patient.

By supporting research in PD-1/PD-L1 checkpoint pathways, we aim to empower scientists to advance more precise, effective, and patient-specific cancer treatments.

🔬 Personalized immunotherapy starts with better research tools.

https://www.youtube.com/watch?v=9AIJAGjVkOc

In 2018, 9.6 million people died from cancer, the second largest cause of death worldwide. Finding a cure to cancer has been the focus of medical science for...

12/18/2025

As the year comes to a close, we’d like to thank our customers, partners, and researchers around the world for your trust and collaboration throughout 2025.

We’re proud to support your work in immunology, oncology, neuroscience, and beyond, and we look forward to continuing this journey together in the year ahead.

Wishing you a joyful holiday season and a successful, inspiring New Year!

🎄❄️✨

12/03/2025

Latest data from the 2025 CTAD conference shows that Eisai’s anti-tau antibody Etalanetug (E2814) dramatically reduces eMTBR-tau243 levels — a blood and CSF biomarker tightly linked to tau tangles — in patients with inherited Alzheimer’s disease. Results suggest tau spreading was inhibited, hinting at real disease-modifying potential for tauopathies.

📉 CSF tau-tangle biomarker down ~62 % at 3 months
📉 Plasma biomarker down ~78 % at 3 months, improving over time

This could pave the way for blood-based monitoring of tau pathology and new therapeutic strategies for Alzheimer’s and related tau disorders.

Read the full article here: https://media-us.eisai.com/2025-12-01-Eisai-Presents-New-Data-on-Anti-Tau-Antibody-Etalanetug-E2814-at-CTAD-2025

Etalanetug demonstrated reduction of eMTBR-tau243, a novel CSF and plasma biomarker that specifically reflects tau tangle pathology, in Phase Ib/II study TOKYO, Dec. 1, 2025 /PRNewswire/ -- Eisai...

11/26/2025

New insights in immune-modulation! A recent Journal of Leukocyte Biology review highlights how anti-TNF therapy doesn’t just neutralize TNF-α — it also reprograms innate immune cells, offering hope for treating systemic autoinflammatory diseases. 🔄 By targeting the root of inflammation, this approach could reshape standards for immune-disease treatment.

Read the full article here: https://academic.oup.com/jleukbio/article-abstract/117/5/qiaf026/8078379

This review explores the clinical relevance of anti-tumor necrosis factor therapy in systemic autoinflammatory diseases, focusing on its impact on innate i

11/19/2025

🔬 New must-read for Alzheimer’s researchers! A fresh review in Alzheimer’s Disease: Clinical Trials to Watch spotlights next-gen therapies tackling tau, amyloid-β, and neuro-inflammation. Better trial design + smarter biomarkers = real hope for AD.
🔗 https://www.sciencedirect.com/science/article/abs/pii/S2666634025001989

11/12/2025

Tsutomu Takeuchi’s article highlights next-gen anti-TNF agents, including nanobody therapeutics like Ozoralizumab, and what’s “new vs old” in RA treatment. Dive into the evolving pipeline and future of TNF-targeted therapy.

Read the full article: https://pubmed.ncbi.nlm.nih.gov/40180877/

This review summarizes the recent advancement of fragmented immunoglobulin molecules targeting on Tumot Necrosis Factor (TNF) alpha and highlighted the nanobody, which is the first approved product for the patients with rheumatoid arthritis (RA), ozoralizumab (OZR). Background for the clinical devel...